Latest Earnings Results: Q2 '26
Estimated EPS
-$0.08
Reported EPS
$0.42
Surprise
+625%
Estimated Rev
$29.21M
Reported Rev
$32.61M
Surprise
+11.62%
$ANIK Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.25 up 189.29% YoY • Reported revenue of $32.61M up 15.56% YoY • Anika Therapeutics, Inc. is raising its full-year 2026 revenue growth guidance to 5% to 10% and its adjusted EBITDA margin outlook to 13% to 17% for the fiscal year.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.23 | -- | -- | N/A |
Q2 '26 | -$0.08 | $0.42 | 625.00% | BEAT |
Q1 '26 | -$0.07 | $0.27 | 485.71% | BEAT |
Q4 '25 | -$0.12 | $0.31 | 348.00% | BEAT |
Q3 '25 | -$0.18 | $0.04 | 122.22% | BEAT |